Intellect Neurosciences CEO to be Featured on Wall Street Reporter

NEW YORK, Oct. 7, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline, and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announces that an interview with Dr. Daniel Chain, Ph.D., Chairman and CEO will be posted on Wall Street Reporter.

Dr. Chain will be discussing the state of the company and the biotechnology industry, recent milestones and upcoming activities at Intellect Neurosciences.  To access this interview, which will only be available through October 10th, please log on to http://www.wallstreetreporter.com/2011/10/intellect-neurosciences-otcbbilns-ceo-interview/.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases especially focused on proteinopathies.  Its pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches including monoclonal antibodies and vaccines targeting beta amyloid and abnormal tau proteins.  Previously, Intellect Neurosciences out-licensed late-stage antibody products based on the company's ANTISENILIN® Alzheimer's beta amyloid monoclonal antibody technology to several major pharmaceutical companies. In addition, the company recently licensed OX1 a small molecule antioxidant to ViroPharma for Friedreich's Ataxia and other neurodegenerative diseases.

Currently, the company is focused on developing next generation antibody therapeutics.  Its most advanced internal candidate is a humanized monoclonal antibody drug conjugate being developed for age-related macular degeneration and other diseases and conditions caused by beta amyloidosis.  For more information, please visit www.intellectns.com.

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2010, and information contained in our Quarterly Report on Form 10-Q for the three month period ended March 31, 2011, filed on May 23, 2011.

Contact
Jules Abraham
Principal
JQA Partners, LLC
917-885-7378
[email protected]

SOURCE Intellect Neurosciences, Inc.

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.